Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Spravato (esketamine) demonstrates superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder – Johnson & Johnson

Written by | 21 Oct 2023

An open-label, international study published in the New England Journal of Medicine found that patients receiving Spravato (esketamine) CIII nasal spray for treatment-resistant depression (TRD) were 1.54 times… read more.

Esketamine shows higher efficacy than quetiapine in treatment-resistant depression

Written by | 19 Oct 2023

Researchers report that patients treated for treatment-resistant depression with esketamine NS (nasal spray), a form of ketamine, achieve better and more durable outcomes than similar patients treated with… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.